Purpose: To evaluate the analgesic effect of ketorolac 0.5% drops during the intravitreal injection procedure.
Methods: Thirty patients (n=30) received topical ketorolac 0.
We report the clinical course of a 56-year-old patient diagnosed with toxic keratopathy due to topical anesthetic abuse. One month later, while a large corneal epithelial defect persisted, the cornea developed circumferential neovascularization that was treated with subconjunctival bevacizumab. Corneal neovascularization (CN) showed a dramatic regression 1 week after subconjunctival injection of bevacizumab.
View Article and Find Full Text PDF